Khanmohammadi Shaghayegh, Masrour Mahdi, Fallahtafti Parisa, Habibzadeh Amirhossein, Schuermans Art, Kuchay Mohammad Shafi
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Diabetes Metab Syndr. 2025 Feb;19(2):103187. doi: 10.1016/j.dsx.2025.103187. Epub 2025 Jan 7.
Frailty is frequently observed in end-stage liver disease of various etiologies, but its role in nonalcoholic fatty liver disease (NAFLD) remains incompletely understood. We aimed to conduct a systematic review and meta-analysis to assess the association and prevalence of frailty in NAFLD.
A systematic review of PubMed/MEDLINE, EMBASE, Web of Science, and Scopus was performed. The random-effects model was used to estimate the pooled prevalence of frailty. Meta-analyzed odds ratios (OR) were calculated to examine the association between frailty and NAFLD.
Among the initial 430 articles identified, 18 studies were included. Three studies involving 3673 participants had a pooled OR of 2.03 (95% CI: 1.51-2.72; Iˆ2 = 1.1%; p < 0.0001) for the association between frailty and NAFLD. The pooled prevalence of frailty in individuals with NAFLD was 23% (95% CI: 13%-38%; Iˆ2 = 93.5%) using the liver frailty index (LFI) and 8% (95% CI: 3%-21%; Iˆ2 = 98.1%) using the Fried frailty index (FFI). NAFLD patients' mean grip strength and balance time were 26.4 kg (95% CI: 23.0-29.8) and 23s (95% CI: 10-35), respectively. Among studies that also included individuals with liver cirrhosis, grip strength was lower in those with cirrhosis vs. the broader population of those with NAFLD.
Our study suggests that frailty is highly prevalent in individuals with NAFLD, with a significantly higher prevalence compared to those without NAFLD. Individuals with NAFLD have more than two-fold increased odds of frailty. Assessing frailty in NAFLD patients enables targeted management to improve outcomes.
衰弱在各种病因的终末期肝病中很常见,但其在非酒精性脂肪性肝病(NAFLD)中的作用仍未完全明确。我们旨在进行一项系统评价和荟萃分析,以评估NAFLD中衰弱的相关性及患病率。
对PubMed/MEDLINE、EMBASE、Web of Science和Scopus进行系统评价。采用随机效应模型估计衰弱的合并患病率。计算荟萃分析的比值比(OR),以检验衰弱与NAFLD之间的相关性。
在最初确定的430篇文章中,纳入了18项研究。三项涉及3673名参与者的研究显示,衰弱与NAFLD之间相关性的合并OR为2.03(95%CI:1.51 - 2.72;Iˆ2 = 1.1%;p < 0.0001)。使用肝脏衰弱指数(LFI)时,NAFLD患者中衰弱的合并患病率为23%(95%CI:13% - 38%;Iˆ2 = 93.5%),使用弗里德衰弱指数(FFI)时为8%(95%CI:3% - 21%;Iˆ2 = 98.1%)。NAFLD患者的平均握力和平衡时间分别为26.4 kg(95%CI:23.0 - 29.8)和23秒(95%CI:10 - 35)。在也纳入了肝硬化患者的研究中,肝硬化患者的握力低于更广泛的NAFLD患者群体。
我们的研究表明,衰弱在NAFLD患者中非常普遍,与无NAFLD者相比患病率显著更高。NAFLD患者发生衰弱的几率增加两倍多。评估NAFLD患者的衰弱情况有助于进行针对性管理以改善预后。